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Abstract
Rare germline mutations in TP53 (17p13.1) cause a highly penetrant predisposition to a
specific spectrum of early cancers, defining the Li-Fraumeni Syndrome (LFS). A germline
mutation at codon 337 (p.Arg337His, c1010G>A) is found in about 0.3% of the population of
Southern Brazil. This mutation is associated with partially penetrant LFS traits and is found
in the germline of patients with early cancers of the LFS spectrum unselected for familial his-
tory. To characterize the extended haplotypes carrying the mutation, we have genotyped 9
short tandem repeats on chromosome 17p in 12 trios of Brazilian p.Arg337His carriers.
Results confirm that all share a common ancestor haplotype of Caucasian/Portuguese-Ibe-
ric origin, distant in about 72–84 generations (2000 years assuming a 25 years intergenera-
tional distance) and thus pre-dating European migration to Brazil. So far, the founder p.
Arg337His haplotype has not been detected outside Brazil, with the exception of two resi-
dents of Portugal, one of them of Brazilian origin. On the other hand, increased meiotic
recombination in p.Arg337His carriers may account for higher than expected haplotype
diversity. Further studies comparing haplotypes in populations of Brazil and of other areas
of Portuguese migration are needed to understand the historical context of this mutation in
Brazil.
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Introduction
A germline TP53mutation in codon 337 (c.1010G>A; p.Arg337His) is present at a high fre-
quency (0.3%) and represents a significant cancer risk factor in the population of Southern Bra-
zil [1–4]. This mutation predisposes to multiple and early cancers that characterize the tumor
spectrum of Li-Fraumeni Syndrome (LFS) and its variant Li-Fraumeni-Like syndrome (LFL)
[5–8]. Initially described in association only with adrenocortical carcinoma (ADC) in Brazilian
children with no familial cancer history (Ribeiro et al., 2001), p.Arg337His was subsequently
identified in the germline of individuals with cancer predisposition matching LFS/LFL criteria,
including early onset breast cancer, soft tissue sarcoma, choroid plexus carcinoma, and phyl-
lodes breast tumors [9–14]. To date, germline p.Arg337His has been reported in over 50 can-
cer-prone Brazilian families and in several hundred of Brazilian cancer patients with no
apparent familial history of cancer. To our knowledge, only 2 instances of the germline muta-
tion have been reported in patients with no known connection with Brazil: a family of Portu-
guese origin matching LFS criteria, with a 8-years old female proband diagnosed with ADC in
France [15,16], and a family of German origin that does not match LFS/LFL criteria, with a 71
year-old proband diagnosed with ADC [17,18].
Despite initial reports suggesting that the mutation may have arisen independently in chil-
dren with apparently sporadic ADC, in-depth analysis of 29 TP53 tag single nucleotide poly-
morphisms in 48 unrelated subjects (45 Brazilians, and 3 Portuguese) demonstrated that the
mutation was present on an identical founder haplotype of Caucasian origin, suggesting that
the p.Arg337His mutation had probably arisen in an individual of European ancestry [15].
Interestingly, this founder haplotype was not detected in the patient from Germany [17,18]
suggesting that in this patient the mutation resulted from an independent event.
In the present study, we have further assessed the ancestry of the founder allele in Brazilian
subjects by haplotyping nine short tandem repeats (STRs) spanning 8Mb on the entire short
arm of chromosome 17 and flanking the TP53 gene at 17p13.1. We estimated mutation age
and compared haplotypes in carriers with those of reference populations from Brazil, Portugal,
Africa, as well as Amerindians in order to infer the population origin of the founder allele.
Materials and Methods
Participants
Patients and cancer-unaffected relatives carrying TP53 p.Arg337His were recruited for the
study after signature of informed consent as this study was approved by the Research Ethics
Committee of the Research and Postgraduate Studies Group from Hospital de Clinicas de
Porto Alegre (CEP-GPPG-HCPA) under protocol number #09–430. DNA samples from 12
apparently unrelated familial trios (father-mother-child) were included. Of these, nine were
recruited from Hospital de Clinicas de Porto Alegre (city of Porto Alegre, in the State of Rio
Grande do Sul, Brazil) and three were recruited from AC Camargo Cancer Center (city of São
Paulo, State of São Paulo, Brazil).
To assess the most likely populational origin of the founder haplotype, we analyzed uniden-
tified DNA samples from different series of cancer-unaffected individuals, which had been pre-
viously obtained for populational genetic analyses in different studies after ethical approval.
These include a series of 250 cancer-unaffected individuals from Southern Brazil (population-
based sample), 270 cancer-unaffected and otherwise asymptomatic subjects from Northern
Portugal [19,20], 120 asymptomatic subjects from the Sub-Saharan region of Africa [21,22]
and 100 individuals from eight Amerindian tribes belonging to four linguistic groups of the
Brazilian Amazon Region [23].
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Genotyping
Genomic DNA was extracted from peripheral blood leukocytes using the Ilustra blood genomic
Prep Mini spin Kit (GE Healthcare, Piscataway, NJ, USA) as described by the manufacturer.
DNA concentration was measured with Nano-Drop 1000 (Thermo Fisher Scientific, Waltham,
MA, USA) and diluted to a final concentration of 10 ng/μl. Direct sequencing of TP53 exons 2
to 11 and flanking splice site junctions was performed in all members of the trios as previously
described [24]. For haplotype analysis, we selected nine short tandem repeat (STRs) markers
spanning a region of 8Mb extending on both sides of the TP53 gene at 17p13 (Fig 1). STR1 to
STR9 markers were PCR amplified using fluorescently end-labeled primers (Table 1), analyzed
on an ABI3130 DNA analyzer and scored using ABI GeneScan Analysis Software (Thermo
Fisher Scientific, Waltham,MA, USA).
Age estimation and ancestry of p.Arg337His
To estimate the age (in generations) of the TP53 p.Arg337His mutation we applied two calcula-
tion methods using DMLE+2.3 [25] and ESTIAGE [26] softwares. DMLE+2.3 allows Bayesian
inference of the generation distance of the most plausible common ancestor based on the
observed linkage disequilibrium at multiple genetic markers in carriers and unrelated non-car-
riers. This method uses a Markov Chain Monte Carlo algorithm taking into account the pro-
portion of disease bearing chromosomes carrying the TP53 p.Arg337His mutation (0.015%)
[2,3], the distances between the markers and the mutation site relative to the markers using
HG19 sequence and 1cM = 1Mb, and an estimated annual Brazilian population growth rate of
9.5%, based on the mean of the Brazilian growth rate for 300 years (45% including reproductive
growth but also including the distinct waves of immigration) and the European growth rate for
1700 years (2.5%). ESTIAGE is a likelihood-based method that uses multilocus marker data
from patients carrying the same mutation, assuming that they descended from a common
ancestor who introduced the mutation. An estimate of the number of generations since the
most recent common ancestor is obtained from the size of the haplotype shared by the individ-
uals on each side of the disease locus. The method uses haplotype information in patients car-
rying the mutation and in control subjects to identify the most likely positions of
recombination events on the ancestral haplotype. A 25-year intergeneration interval was used
for both methods with a mutational rate of 10−4 for the nine STRs analyzed.
After genotypes were established, haplotype frequencies were estimated using the ARLE-
QUIN v3.5 software [27] in 500 chromosomes from unrelated control individuals from Porto
Alegre, 540 chromosomes from unrelated Portuguese individuals, 240 chromosomes from
unrelated African individuals and 200 chromosomes from Native American individuals.
ARLEQUIN v3.5 was also used to compare the ancestral haplotype in which the p.Arg337His
mutation is present with the constructed parental population haplotypes, assuming that the
most likely parental population would present the least average pairwise difference with the
ancestral haplotype in which the p.Arg337His mutation is present [28,29].
Results
Age estimation of the TP53 p.Arg337His mutation
To establish the correct haplotype in which the p.Arg337His allele is present, we used genotype
data from the nine STRs analyzed in twelve trios. Observed haplotypes of individuals carrying
the p.Arg337His allele are shown in Table 2. Analysis of the nine STR markers in twelve trios
using the ESTIAGE software revealed that all extended haplotypes carrying the p.Arg337His
mutation included in this study derive from a common ancestor haplotype which was
TP53 p.Arg337His Mutation: Age and Origin
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introduced in the population 84 generations ago (95% CI: 54–135). For estimating the genera-
tion distance using the DMLE+2.3 software, the haplotype frequencies from the Portuguese
control population were constructed using ARLEQUIN as a reference. Analysis of linkage dis-
equilibrium in carriers and non-carriers estimated that the p.Arg337His mutation was present
on a haplotype that might have been introduced 72 generations ago (95% CI 50–105) (Fig 2).
Based on these two approaches and using a pre-established 25-year intergeneration interval,
the age of the TP53 p.Arg337His mutation appears to be of approximately of 2000 years.
Fig 1. Short TandemRepeats position used for haplotype analysis and their respective position in
chromosome 17p.
doi:10.1371/journal.pone.0143262.g001
Table 1. Primers and Short TandemRepeats genomic position.
STR Repeat Genomic Position Primers
STR-1 (AATA)n 5235917 F - 6FAM 50TTAGGAAAGGGTTGCCAGATTA and R - 50CAAACTTCCCTTGACCATCACT
STR2 (ACAC)n 5676955 F - 50ACTCCAGCATGGGTAACAGAGT and R - 6FAM 50TATCCCAACCATATCCTCCAAA
STR-3 (TGAGC)n 5913810 F - NED 50ACATACGAAGCATCCAGTGAAG and R - 50AGGATTAGCATCAGGTTTCCAG
STR-4 (TGTTT)n 6154523 F - NED 50TGACTTTTGGGACTTTGTGTGT and R - 50GGAGACAGAGGTTGCAGTGAG
STR-5 (AAAC)n 7534398 F - 50GGACAGAGCAAAACTCCATCTC and R - PET 50ATTTCTGGGAGGACACAACAAG
STR-6 (ATAG)n 8600727 F - VIC 50ACACGGAACGGAATATCCTACA and R - 50GCACCTGTACTCCCAGCTACTT
STR-7 (ATAA)n 9248467 F - PET 50ATATGGATGGGAGGACAAGAGA and R - 50GGATGGATGGATAGGCAGATAG
STR-8 (GCAC)n 12351781 F - 6FAM 50CACCACAAACTTTATTGCTTCG and R - 50CTAAATCTGCAAGTCCCCTTTG
STR-9 (AGC)n 12800569 F - VIC 50GGATGAAGTAAGGGCAATGAAC and 9R - 50GCTTGGACGACAGAGTGAGAC
doi:10.1371/journal.pone.0143262.t001
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Population origin of the TP53 p.Arg337His mutation
In order to identify the most likely population origin of the TP53 p.Arg337His mutation, we
genotyped individuals from parental populations that contributed to the current admixed Bra-
zilian population, as described in the methods section. Using ARLEQUIN v3.1 to identify the
most likely origin based on the average pairwise differences between the parental population
haplotypes and the twelve haplotypes carrying the mutation (Table 3), we observed that the
founder p.ArgR377His haplotype had the highest homology with the haplotypes of Portuguese
(Average Pairwise Difference = 1.71096, P<0.001) and Brazilian reference population, and the
Table 2. TP53 p.R337Hmutation carrier’s haplotypes.
STR-1 STR-2 STR-3 STR-4 STR-5 R337H STR-6 STR-7 STR-8 STR-9
POA-1 270 181 138 225 224 337H 262 167 112 191
POA-2 248 189 108 245 224 337H 262 167 112 203
POA-3 248 189 108 245 224 337H 262 167 108 191
POA-4 248 189 108 245 224 337H 262 163 108 203
POA-5 270 189 108 245 224 337H 270 175 108 191
POA-6 274 189 108 245 224 337H 262 171 112 191
POA-7 274 189 108 245 224 337H 262 167 112 191
POA-8 274 189 108 245 224 337H 282 175 112 191
POA-9 248 189 143 245 224 337H 262 167 108 191
SP-1 274 189 108 245 224 337H 262 159 108 191
SP-2 248 181 138 235 224 337H 262 167 112 191
SP-3 270 185 138 245 224 337H 262 167 112 194
Shared haplotypes are highlighted in bold.
doi:10.1371/journal.pone.0143262.t002
Fig 2. Age estimation for the p.Arg337His mutation as assessed by DMLE+2.3.Green lines show 95%CIs.
doi:10.1371/journal.pone.0143262.g002
TP53 p.Arg337His Mutation: Age and Origin
PLOS ONE | DOI:10.1371/journal.pone.0143262 November 30, 2015 5 / 11
lowest homology with haplotypes of Amerindian and African ancestries. These results rein-
force previous indications that the haplotype carrying p.Arg337His is of European/Caucasian
origin [15], and suggest a Portuguese-Iberic origin, although subgroups of European ancestry
were not analyzed.
Discussion
Analysis of 9 STRs on the short arm of chromosome 17p in 12 unrelated trios from Brazilian
families carrying the TP53 p.Arg337His mutation confirms that all carriers have a common
ancestry. Comparing the most plausible ancestor haplotype with those present in populations
contributing to the current admixed population of Brazil, the founder haplotype appears to be
of European/Portuguese-Iberic origin. Furthermore, estimates of the generation distance to the
common ancestor of the 12 trios analyzed suggest that p.Arg337His carriers are separated by
about 72–84 generations, representing approximately 2000 years assuming a 25 years intergen-
erational distance. Consistent estimates were obtained with two different computational
approaches to calculate generational distance, using either the DMLE+2.3 (72 generations) and
ESTIAGE (84 generations) softwares. It is important to note that current evidence does not
show increased recombination rates in carriers of germline TP53mutations [29], and although
recombination rates are heterogeneous across the genome with higher rates in certain chromo-
somes (including chromosome 17), a recombination rate up to 20% over baseline would not
significantly impact age estimation as calculated here [28,30]. These results confirm, strengthen
and extended previous studies [15] demonstrating a founder effect based on the analysis of
intragenic TP53 polymorphism and provide novel information on the diversity of the extended
haplotypes that are present in p.Arg337His carriers. The present study differs from Garritano’s
in two main aspects. First, Garritano’s paper was focused in confirming whether p.Arg337His
is a founder mutation and present in depth TP53 sequencing data to provide the answer to this
question, while our main goal was to determine mutation age and obtain insights about muta-
tion origin. Second, in terms of methodology, Garritano et al analyzed intragenic TP53 single
nucleotide polymorphisms, while we focused on STR markers spanning a region of 8Mb down-
stream and upstream of the TP53 gene. We chose this approach because the STRs used are
positioned in non-coding regions of the genome being biologically silent, which enables accu-
mulation of mutations unhindered over the generation, facilitating the identification of molec-
ular variability. Indeed, Garritano et al. suggested that the analysis of an extended haplotype
would help to correctly identify the datation of the founder effect demonstrated by their work.
The 12 trios who contributed DNA for this analysis are from families of apparent European
origin, established in Southern Brazil since an unknown number of generations. The current
Brazilian population is the result of five centuries of admixture between different continental
ancestries (Europeans, Africans and Amerindians) [31–33]. Although the majority of the con-
tribution to the current gene pool is European in all Brazilian regions, Amerindian and African
ancestries are have a higher representation in the population of Northern and North-Eastern
Brazil (about 4 million African individuals are estimated to have been brought to Brazil as
Table 3. Average Pairwise Differences Among Haplotypes.
R337H carriers Haplotypes P-Value
Portuguese 1.71096 <0.001
Brazilians 1.75029 <0.001
Amerindians 2.37292 <0.001
Africans 2.76101 <0.001
doi:10.1371/journal.pone.0143262.t003
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slaves between the years 1700 and 1850). In contrast, the population of Southern and South-
eastern Brazil shows higher proportions of European ancestries, probably due to waves of
immigration between 16th and mid-20th centuries. The first large wave of immigrants (1500
and 1800) was of Portuguese origin (estimated to about 0.5 millions), followed by successive
waves of Germans, Italians, Hispanics, Jews and Japanese, together amounting to about 5 mil-
lion settlers who are the origin of the current population [34]. Presence of p.Arg337His on a
haplotype of Portuguese ancestry is consistent with the population structure of Southern Brazil,
where carriers and their families originate. The largest known mutation-positive family
includes 9 documented generations and originates from an ancestor of Portuguese origin who
reportedly settled in the area of São Paulo in the final years of the 17th century [14].
It is estimated that p.Arg337His carriers represent about 0.3% of the population of Southern
Brazil, in a large area extending from the States of Rio de Janeiro (RJ) and Minas Gerais (MG)
to the North and North-West, to Rio Grande do Sul (RS) to the South, and encompassing also
the States of Parana (PR) and Santa Catarina (SC). Overall, the population of these States
amounts to about 100 million, suggesting that about 300,000 of today’s Brazilians may be p.
Arg337His carriers. These estimates are based on a small prevalence study in the area of Porto
Alegre, State of Rio Grande do Sul (RS; 750 subjects, 2 p.Arg337His carriers; Palmero et al.,
2009) and on population-based newborn screening in the State of Paraná (171,469 subjects;
461 carriers; Custódio et al., 2012). These numbers, as well as the wide geographic extension of
carriers, suggest that Portuguese migrants introduced the mutation in the first decades of colo-
nization, before the spread of Portuguese explorers and settlers in Southern Brazil in the middle
of the 17th century. To date, studies on cancer-prone families and on patients with different
core tumors of the LFS/LFL syndromes have identified several hundred Brazilian carriers
[1,3,11,14,35–37]. There is currently no data on the prevalence of the mutation in other popu-
lations, with only 3 documented instances of the mutation in subjects living outside Brazil.
Two were probands from LFS/LFL families diagnosed in Portugal [18] and France, [38] and
both were found carry to the same mutant TP53 haplotype observed in Brazilian carriers. The
proband detected in Portugal was of Brazilian origin (reverse-migrant to Portugal), whereas
the proband tested in France resided in Portugal, with no information available on a possible
Brazilian origin. The third reported occurrence of p.Arg337His outside Brazil is a cancer
patient with no LFS/LFL history residing in Germany, who carried the mutation on a different
TP53 background than Brazilian subjects [17,18]. This patient had no known Portuguese or
Brazilian ancestry and may represent an independent occurrence of the mutation, a finding
consistent with the fact that the G>Amutation at position 1100 is located within a CpG site, a
sequence context which is intrinsically highly mutable.
The worldwide expansion of Portuguese explorers, merchants and immigrants between the
16th and 17th centuries has served as vector for well-documented founder genetic effects.
Machado-Joseph Disease (MLD) is a dominant form of ataxia caused by a mutation originating
in Asia dispersed around the world by Portuguese merchants, sailors and travellers [39]. The
BRCA2 c.156_157insAlu mutation, which accounts for 37.9% of all mutations in families with
hereditary breast and ovarian cancer (HBOC) in Portugal, is carried by a Portuguese haplotype
occasionally found in countries of Portuguese immigration. In Brazil, this mutation has been
observed in 3/168 unrelated HBOC patients from RJ in Brazil, but in none of 144 HBOC pro-
bands from SP and RS, Brazil [40]. The estimated age this mutation is 558 ± 215 years, consis-
tent with a temporal origin around the time of the first waves of Portuguese migration.
Another Portuguese founder mutation has been observed inMSH2 (c.388-389 delCA) associ-
ated with Lynch syndrome in families from Northern Portugal. The estimated age of this muta-
tion is less than 300 years ago and it has also been reported in Brazilian families with Lynch
syndrome [41,42]. In addition, Portuguese founder mutations have been observed among
TP53 p.Arg337His Mutation: Age and Origin
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Brazilian patients with other genetic disorders, but different from the TP53 p.Arg337His muta-
tion, they continue to occur at relatively high frequency in their populations of origin [43,44].
Our estimate for the age of the mutation should be considered with caution. First, because
absolutely precise population growth rates for the last 500 years in Brazil cannot be established,
and we have used, as have many others, an estimate of this growth (Fig 3). Second, an apparent
generation distance of 72–84 generations, amounting to about 2000 years, implies that the
mutation has arisen in an ancestor living about 1,500 years before the arrival of the first Portu-
guese-Iberic settlers in Latin America. Furthermore, the fact that this 2000-year haplotype
diversity is observed among Brazilians themselves implies that the current population of Brazil-
ian p.Arg337His carriers originated from several distantly related ancestors who where sepa-
rated by at least 50 generations (about 1000 years) at the time of their arrival on the Latin
American continent. Indeed, assuming a 2000-years old history for the p.Arg337His haplotype,
its geographic spread in Brazil cannot have taken place before the early 18th to mid-19th cen-
tury, when the first large waves of migrants of Europeans settled in Southern Brazil. Finally, if
the mutation is indeed European in origin, one would expect to observe it at more significant
frequencies in European LFS/LFL families. Thus, a more detailed analysis of the common
ancestry of p.Arg337His carriers, and perhaps an extended mutation search in other popula-
tions may be needed to understand the historical geographical spread of this alteration.
Fig 3. Brazilian Population Growth between 1550–2000.
doi:10.1371/journal.pone.0143262.g003
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